Substitution of antithrombin III in shock and DIC: a randomized study

Area of Science:

• Critical Care Medicine
• Hematology
• Pharmacology

Background:

• Disseminated Intravascular Coagulation (DIC) is a life-threatening condition often associated with shock.
• Antithrombin III (AT III) plays a crucial role in regulating coagulation.
• Heparin is commonly used in managing DIC, but its efficacy alongside AT III substitution is debated.

Purpose of the Study:

• To evaluate the efficacy and safety of Antithrombin III (AT III) substitution compared to heparin or combination therapy in shock patients with DIC.
• To assess the impact of AT III substitution and heparin on coagulation parameters and clinical outcomes.

Main Methods:

• A study involving 51 shock patients diagnosed with DIC.
• Patients were treated with either AT III substitution, heparin, or a combination of both.
• Key parameters monitored included AT III levels, platelet count, C1 esterase inhibitor, and blood loss.

Main Results:

• AT III substitution led to higher AT III concentrations than activity.
• Heparin administration resulted in a drop in platelet count.
• Combined therapy showed increased blood loss and no added benefit over AT III substitution alone, with shorter DIC symptom duration in substituted groups.

Conclusions:

• Additional heparin administration does not improve the therapeutic effect of AT III substitution in DIC patients.
• Simultaneous administration of AT III and heparin may increase the risk of side effects like thrombocytopenia and heightened blood loss.